Stock A048410 HYUNDAI BIOSCIENCE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hyundai Bioscience Co., Ltd.

Equities

A048410

KR7048410005

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
20,300 KRW +3.89% Intraday chart for Hyundai Bioscience Co., Ltd. +1.25% -22.22%
05-20 Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd.. CI
05-16 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd..
CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank
CI
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil
CI
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer
CI
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer
CI
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection
CI
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.
CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd.
CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion.
CI
Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA
CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials
CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A048410 Stock
  4. News Hyundai Bioscience Co., Ltd.